There are currently 30,000 people with CF in united states. This drug can only be used by CF patients with a specific mutation, not the entire population. And

There are currently 30,000 people with CF in united states. This drug can only be used by CF patients with a specific mutation, not the entire population. And I wouldn't assume $180M since this treatment is a combination of 3 different drugs all with their own development pathway and safety testing. Then you need to look at the actual cost of manufacturing the drug, packaging it, delivering it to patients and all the salaries of the people it takes to do that. Sales of $180M is not profit, it's revenue. Don't get me wrong, they are making a profit, but pharma company profit margins are usually in the 20-30% range and that's for the successful ones, not including all the companies that spend $100M and fail with nothing to show for it. Then add on top the remaining patent life which is usually less than 10 years, after which the cost of the drug will plummet and the originator company will stop making money.